Kaddoura Malak, AlIbrahim Malak, Hijazi Ghina, Soudani Nadia, Audi Amani, Alkalamouni Habib, Haddad Salame, Eid Ali, Zaraket Hassan
Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Front Pharmacol. 2020 Aug 6;11:1196. doi: 10.3389/fphar.2020.01196. eCollection 2020.
Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19-associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients.
自2019年12月在中国出现以来，新型冠状病毒肺炎（COVID-19）迅速在全球传播，引发了一场大流行。接种疫苗或发展群体免疫似乎是减缓病毒传播的唯一途径；然而，在不久的将来这两者都无法实现。因此，迫切需要有效的治疗方法来减轻这场大流行的负担并降低死亡率。正在进行针对潜在抗病毒和免疫调节化合物及分子的临床前和临床研究，以确定用于治疗COVID-19的安全有效的疗法。到目前为止，两种化合物，瑞德西韦和地塞米松已显示可降低与COVID-19相关的死亡率。在此，我们综述了正在考虑用于治疗和管理COVID-19患者的潜在治疗药物。
